Rezatapopt

Phase 1Small molecule

PPMV Pharmaceuticals, Inc

Rezatapopt is one of 84 small molecule programs targeting Advanced Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorRecruiting

Solid TumorRecruiting

TP53 Y220C MutationRecruiting

Advanced Solid TumorPreclinical

Recruiting

Solid TumorPreclinical

Recruiting

TP53 Y220C MutationPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

DATROWAY

Daiichi Sankyo

Preclinical

1 2

Fludara

Sanofi

Preclinical

1 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 4

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 5

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 6

Navmi

SSummit Therapeutics

Preclinical

1 7

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 9

Soc

Pfizer

Preclinical

1 10

PD-1 Inhibitor

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Solid Tumor

NCT04585750

Q1 2028

Phase 1Recruiting

TP53 Y220C Mutation

NCT07372625

Q3 2029

Phase 1Recruiting

Myelodysplastic Syndrome

NCT06616636

Clinical

Trials by Indication[1]

Solid Tumor1 trial

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Recruiting·PPMV Pharmaceuticals, Inc·Preclinical·NCT04585750·300 enrolled

Myelodysplastic Syndrome1 trial

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06616636·24 enrolled

TP53 Y220C Mutation1 trial

A Phase 1, Open-label, 2-part, Drug-Drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Recruiting·PPMV Pharmaceuticals, Inc·Phase 1·NCT07372625·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Rezatapopt. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rezatapopt compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rezatapopt. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PMV Pharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPMV Pharmaceuticals, Inc

Rezatapopt

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q3 2029

Trials by Indication[1]

Solid Tumor1 trial

Myelodysplastic Syndrome1 trial

TP53 Y220C Mutation1 trial

References

Drug Info

Quick Facts

Related News